Individuals with genetic diseases have an increased chance of lower quality of life. However, a new technology has been developed that could edit DNA and take out possible mutations resolving genetic ...
Broad Institute CRISPR-Cas9 technology will be combined with DefiniGEN’s best-in-class induced Pluripotent Stem Cell (iPSC) differentiation platform to generate preclinical cell models which can ...
Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...
The Food and Drug Administration (FDA) approved the gene therapy Casgevy in December, which uses CRISPR/Cas9 genome editing technology to treat sickle-cell disease (SCD) in patients twelve years and ...
This is a preview. Log in through your library . Abstract CRISPR/Cas9 technology has immense power to reproduce plants with desired characters and revolutionizing the field of genome engineering by ...
CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...
SEOUL, South Korea, Nov. 19, 2025 /PRNewswire/ -- ToolGen (KOSDAQ: 199800; CEO Jong-sang Ryu), a leader in genome editing technology, announced that the United States Patent and Trademark Office has ...
CRISPR-Cas9 gene editing holds immense potential in the field of precision medicine for liver diseases. This innovative technology permits researchers to precisely modify genes linked to liver ...
The United Nations predicts that there will be an additional 2.2 billion people on the planet by 2050. To help feed the growing population, the food industry must overcome several critical challenges, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback